viewFutura Medical PLC

Futura Medical PLC - Futura to Update on MED3000 at Investor Seminar

RNS Number : 0384F
Futura Medical PLC
05 March 2020


05 March 2020


Futura Medical to Present "FM57" Clinical Data and Provide Update on MED3000 at Investor Seminar in March 2020


Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its on its proprietary, transdermal technology DermaSys®  and currently focused on sexual health and pain, announces plans to host an Investor Seminar in London for analysts and institutional investors on Thursday, 26 March 2020.


The seminar follows an extensive internal evaluation of the clinical data from the Phase 3 study ("FM57") announced on 10 December 2019. Ken James, Executive Director and Head of R&D will present the Company's ongoing research and analysis of the FM57 and MED3000


James Barder, Chief Executive Officer of Futura Medical, said: "FM57 results demonstrate that MED3000 is a highly effective, safe and differentiated therapy for ED. After an extensive internal evaluation of the FM57 clinical data, we are pleased to be able to share our ongoing clinical and literature-based research and analysis, examining MED3000 efficacy and modes of action in ED. In addition, following positive interactions with an EU Notified Body announced in February 2020, we look forward to providing the market with further updates regarding the formal proceedings of MED3000 to be approved as a medical for treatment of ED."


The seminar will also feature a presentation from Professor David Ralph, world leading expert in erectile dysfunction and male infertility and member of the Futura European KOL Advisory Panel, providing an insight into the ED market.


Professor David Ralph is a leading Consultant in the field of Andrology. He practices both privately and on the NHS, and holds a senior consultant post at the University College London Hospital. He is a Professor at the Cranfield University and is a senior lecturer at the Institute of Urology, London. Professor David's main areas of expertise are penile implants, total genital reconstruction, Peyronie's disease and male infertility. He is internationally recognised for his work.


For further information on the Investor Seminar, or to register your interest, please contact Optimum Strategic Communications at [email protected]. Further information will be made available in March 2020.


The event will be webcast and will be made available on the investor section of website shortly after the event.


For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: [email protected] 

Tel: +44 (0) 1483 685 670


Nominated Adviser and Sole Broker:


Bidhi Bhoma/ Euan Brown/ Kane Collings

Tel: +44 (0) 20 3100 2000


For media enquiries please contact:


Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [email protected]

Tel: +44 (0) 203 950 9144

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Futura Medical PLC

Price: 22

Market: AIM
Market Cap: £54.04 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18